Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer

  • Jim Zhong
  • Jeffrey Switchenko
  • Madhusmita Behera
  • David Kooby
  • Shishir K. Maithel
  • Mark W. McDonald
  • Jolinta Y. Lin
  • Richard J. Cassidy
  • Bassel El-Rayes
  • Jerome Landry
  • Pretesh R. Patel
Pancreatic Tumors
  • 129 Downloads

Abstract

Background

The LAP07 randomized trial calls into question the role of radiation therapy (RT) in the modern treatment of locally advanced pancreatic cancer (LAPC). However, advances in chemotherapy and RT limit application of the LAP07 results to current clinical practice. Here we utilize the National Cancer Database (NCDB) to evaluate the effects of RT in patients receiving chemotherapy for LAPC.

Methods

Using the NCDB, patients with American Joint Committee on Cancer (AJCC) clinical stage T2–4, N0–1, M0 adenocarcinoma of the pancreas from 2004 to 2014 were analyzed. Patients were stratified into chemotherapy only (CT) and chemoradiation (CRT) cohorts. Patients undergoing definitive RT, defined as at least 20 fractions or ≥ 5 Gy per fraction [i.e., stereotactic body radiation therapy (SBRT)] were included in the CRT cohort. Propensity-score matching (PSM) and landmark analysis were used to address selection bias and lead-time bias, respectively.

Results

13,004 patients met inclusion criteria, of whom 7034 (54%) received CT and 5970 (46%) received CRT. After PSM, 5215 patients remained in each cohort. The CRT cohort demonstrated better overall survival (OS) compared with CT alone, with median and 1-year OS of 12 versus 10 months, and 50% and 41%, respectively (p < 0.001). On multivariable analysis, CRT was associated with superior OS with hazard ratio of 0.79 (95% confidence interval 0.76–0.83) compared with CT alone.

Conclusions

In our series, addition of definitive radiotherapy to CT was associated with better OS when compared with CT alone in LAPC. Definitive radiotherapy should remain a treatment option for LAPC, but optimal selection criteria remain unclear.

Notes

Disclosure

None.

Supplementary material

10434_2017_6322_MOESM1_ESM.jpeg (113 kb)
Supplementary material 1 (JPEG 112 kb)

References

  1. 1.
    Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: pancreas cancer http://seer.cancer.gov/statfacts/html/pancreas.html.
  2. 2.
    Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995;221(6):721–731 (discussion 731–723).CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–1057.CrossRefPubMedGoogle Scholar
  4. 4.
    Kooby DA, Gillespie TW, Liu Y, et al. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Ann Surg Oncol. 2013;20(11):3634–3642.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gastrointestinal Tumor Study Group. Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 1979;5(9):1643–1647.CrossRefGoogle Scholar
  6. 6.
    Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80(10):751–755.CrossRefGoogle Scholar
  7. 7.
    Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–1853.CrossRefPubMedGoogle Scholar
  8. 8.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.CrossRefPubMedGoogle Scholar
  9. 9.
    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.CrossRefGoogle Scholar
  10. 10.
    Shaib WL, Hawk N, Cassidy RJ, et al. A phase 1 study of stereotactic body radiation therapy dose escalation for borderline resectable pancreatic cancer after modified FOLFIRINOX (NCT01446458). Int J Radiat Oncol Biol Phys. 2016;96(2):296–303.CrossRefPubMedGoogle Scholar
  11. 11.
    Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010;78(3):735–742.CrossRefPubMedGoogle Scholar
  12. 12.
    Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128–137.CrossRefPubMedGoogle Scholar
  13. 13.
    Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115(3):665–672.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhong J, Patel K, Switchenko J, et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017;123(18):3486–3493.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Menck HR, Cunningham MP, Jessup JM, et al. The growth and maturation of the National Cancer Data Base. Cancer. 1997;80(12):2296–2304.CrossRefPubMedGoogle Scholar
  16. 16.
    Partridge EE. The National Cancer Data Base: ten years of growth and commitment. CA Cancer J Clin. 1998;48(3):131–133.CrossRefPubMedGoogle Scholar
  17. 17.
    Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567–579.CrossRefPubMedGoogle Scholar
  18. 18.
    Nickleach D LY, Shrewsberry A, Ogan K, Kim S, Wang SAS® Macros to Conduct Common Biostatistical Analyses and Generate Reports. In: SESUG 2013: The Proceeding of the SouthEast SAS User Group. 2013.Google Scholar
  19. 19.
    Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26(4):734–753.CrossRefPubMedGoogle Scholar
  20. 20.
    Lin DY WL. The robust inference for the Cox proportional hazards model. J Am Stat Assoc.1989;84(408):1074–1078.CrossRefGoogle Scholar
  21. 21.
    Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31(23):2963–2969.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Loehrer PJ, Sr., Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105–4112.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592–1599.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Jim Zhong
    • 1
    • 2
  • Jeffrey Switchenko
    • 2
    • 3
  • Madhusmita Behera
    • 2
    • 5
  • David Kooby
    • 2
    • 4
  • Shishir K. Maithel
    • 2
    • 4
  • Mark W. McDonald
    • 1
    • 2
  • Jolinta Y. Lin
    • 1
    • 2
  • Richard J. Cassidy
    • 1
    • 2
  • Bassel El-Rayes
    • 2
    • 5
  • Jerome Landry
    • 1
    • 2
  • Pretesh R. Patel
    • 1
    • 2
  1. 1.Department of Radiation OncologyEmory UniversityAtlantaUSA
  2. 2.Winship Cancer InstituteEmory UniversityAtlantaUSA
  3. 3.Department of Biostatistics & BioinformaticsEmory UniversityAtlantaUSA
  4. 4.Department of SurgeryEmory UniversityAtlantaUSA
  5. 5.Department of Hematology and Medical OncologyEmory UniversityAtlantaUSA

Personalised recommendations